Gomekli Shortage Update: What Patients Need to Know in 2026

If you've been prescribed Gomekli (mirdametinib) for neurofibromatosis type 1 with plexiform neurofibromas and you're struggling to get it filled, you're not alone — but the situation may not be quite what you expect. Here's the current status of Gomekli availability in 2026 and what patients need to know.

Is Gomekli Currently in Shortage?

As of 2026, Gomekli (mirdametinib) is not listed on the FDA's official Drug Shortage Database. The FDA's shortage database tracks medications experiencing supply disruptions due to manufacturing issues, raw material problems, or distribution failures. Gomekli does not currently meet those criteria.

However, "no official shortage" is not the same as "easy to get." Gomekli is a newly approved specialty drug — it received FDA approval in February 2025 — and its distribution infrastructure is still maturing. Access challenges are real, and they can delay treatment for patients who need it.

Why Gomekli Can Be Hard to Access Despite No Official Shortage

There are several structural reasons why NF1 patients may experience delays getting Gomekli:

Specialty pharmacy only: Gomekli is not stocked at retail pharmacies. It must be dispensed through authorized specialty pharmacies.

Prior authorization requirements: Insurance companies almost universally require prior authorization for Gomekli, which can take days to weeks to process.

Limited specialty pharmacy network: Not all specialty pharmacies carry Gomekli, especially in less populated regions.

New drug learning curve: Some insurers and specialty pharmacies are still establishing their processes for handling Gomekli claims and orders.

Rare disease, fewer prescribers: NF1 specialists who are experienced with Gomekli may not be available in all regions, and prescribing guidance is still being established.

A Brief History of Gomekli's Availability

Prior to Gomekli's FDA approval on February 11, 2025, adults with NF1-PN had no FDA-approved medical treatment. The only approved drug was Koselugo (selumetinib), which had been approved in 2020 only for children. Adults who needed treatment were often prescribed selumetinib off-label, which routinely led to insurance denials and delays.

Gomekli's approval was a watershed moment — finally providing a formally approved option for both adults and children with NF1-PN. SpringWorks Therapeutics received Priority Review, Fast Track, and Orphan Drug designations from the FDA, reflecting the urgent unmet medical need. The European Medicines Agency issued a positive opinion recommending conditional marketing authorization for mirdametinib (as Ezmekly) in May 2025, expanding the drug's global reach.

What Should Patients Do Right Now?

If you're having difficulty accessing Gomekli, here are the most effective steps to take:

Contact SpringWorks CareConnections immediately (844-227-3755). A Nurse Advocate can run a benefits investigation, help with prior authorization, and connect you with an authorized specialty pharmacy.

Ask about bridge supply — eligible patients experiencing insurance delays may qualify for temporary free medication through CareConnections while coverage is being sorted out.

Work with your specialist to ensure all supporting documentation for your prior authorization is complete and accurate, including NF1 diagnosis confirmation, PN imaging reports, and documentation of inoperability.

Use medfinder to identify which specialty pharmacies near you can currently fill your Gomekli prescription — without spending hours on hold.

What If I Have to Wait?

If you cannot access Gomekli and your clinical situation requires treatment, discuss the alternative with your NF1 specialist. Koselugo (selumetinib) is an FDA-approved MEK inhibitor for NF1-PN and may be appropriate depending on your age, weight, and clinical situation. Your specialist is in the best position to advise on whether switching or waiting is the right approach.

Read our detailed guide on alternatives to Gomekli for a full breakdown of your options if you can't fill your prescription right now.